Cellular Uptake of Imatinib into Leukemic Cells is Independent of Human Organic Cation Transporter 1 (OCT1)

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2013 Dec 20

PMID 24352644

Citations 29

Authors

Anne T Nies

Elke Schaeffeler

Heiko van der Kuip

Ingolf Cascorbi

Oliver Bruhn

Michael Kneba

Christiane Pott

Ute Hofmann

Christopher Volk

Shuiying Hu

Sharyn D Baker

Alex Sparreboom

Peter Ruth

Hermann Koepsell

Matthias Schwab

Affiliations

Soon will be listed here.

Abstract

Purpose: In addition to mutated BCR-ABL1 kinase, the organic cation transporter 1 (OCT1, encoded by SLC22A1) has been considered to contribute to imatinib resistance in patients with chronic myeloid leukemia (CML). As data are conflicting as to whether OCT1 transports imatinib and may serve as a clinical biomarker, we used a combination of different approaches including animal experiments to elucidate comprehensively the impact of OCT1 on cellular imatinib uptake.

Experimental Design: Transport of imatinib was studied using OCT1-expressing Xenopus oocytes, mammalian cell lines (HEK293, MDCK, V79) stably expressing OCT1, human leukemic cells, and Oct1-knockout mice. OCT1 mRNA and protein expression were analyzed in leukemic cells from patients with imatinib-naïve CML as well as in cell lines.

Results: Transport and inhibition studies showed that overexpression of functional OCT1 protein in Xenopus oocytes or mammalian cell lines did not lead to an increased cellular accumulation of imatinib. The CML cell lines (K562, Meg-01, LAMA84) and leukemic cells from patients expressed neither OCT1 mRNA nor protein as demonstrated by immunoblotting and immunofluorescence microscopy, yet they showed a considerable imatinib uptake. Oct1 deficiency in mice had no influence on plasma and hepatic imatinib concentrations.

Conclusions: These data clearly demonstrate that cellular uptake of imatinib is independent of OCT1, and therefore OCT1 is apparently not a valid biomarker for imatinib resistance.

Citing Articles

Molecular biomarkers of leukemia: convergence-based drug resistance mechanisms in chronic myeloid leukemia and myeloproliferative neoplasms.

Kaehler M, von Bubnoff N, Cascorbi I, Gorantla S Front Pharmacol. 2024; 15:1422565.

PMID: 39104388 PMC: 11298451. DOI: 10.3389/fphar.2024.1422565.

Current Progress on the Influence Human Genetics Has on the Efficacy of Tyrosine Kinase Inhibitors Used to Treat Chronic Myeloid Leukemia.

Prakash T, Enkemann S Cureus. 2024; 16(3):e56545.

PMID: 38646295 PMC: 11027790. DOI: 10.7759/cureus.56545.

Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic Myeloid Leukemia.

Verhagen N, Koenderink J, Blijlevens N, Janssen J, Russel F Pharmaceutics. 2023; 15(11).

PMID: 38004514 PMC: 10675650. DOI: 10.3390/pharmaceutics15112535.

Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia.

Kaehler M, Cascorbi I Handb Exp Pharmacol. 2023; 280:65-83.

PMID: 36882601 DOI: 10.1007/164_2023_639.

The Role of Organic Cation Transporters in the Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of Tyrosine Kinase Inhibitors.

Xiu F, Rausch M, Gai Z, Su S, Wang S, Visentin M Int J Mol Sci. 2023; 24(3).

PMID: 36768423 PMC: 9917293. DOI: 10.3390/ijms24032101.

References

Druker B, Guilhot F, OBrien S, Gathmann I, Kantarjian H, Gattermann N . Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355(23):2408-17. DOI: 10.1056/NEJMoa062867. View

Druker B . Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008; 112(13):4808-17. DOI: 10.1182/blood-2008-07-077958. View

Kell D, Dobson P, Oliver S . Pharmaceutical drug transport: the issues and the implications that it is essentially carrier-mediated only. Drug Discov Today. 2011; 16(15-16):704-14. DOI: 10.1016/j.drudis.2011.05.010. View

Sprowl J, Ciarimboli G, Lancaster C, Giovinazzo H, Gibson A, Du G . Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc Natl Acad Sci U S A. 2013; 110(27):11199-204. PMC: 3704038. DOI: 10.1073/pnas.1305321110. View

Giannoudis A, Wang L, Jorgensen A, Xinarianos G, Davies A, Pushpakom S . The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. Blood. 2012; 121(4):628-37. DOI: 10.1182/blood-2012-01-405035. View

Quintas-Cardama A, Cortes J . Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2008; 113(8):1619-30. PMC: 3952549. DOI: 10.1182/blood-2008-03-144790. View

Marin D, Ibrahim A, Lucas C, Gerrard G, Wang L, Szydlo R . Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2011; 30(3):232-8. PMC: 6366954. DOI: 10.1200/JCO.2011.38.6565. View

Wang D, Jonker J, Kato Y, Kusuhara H, Schinkel A, Sugiyama Y . Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther. 2002; 302(2):510-5. DOI: 10.1124/jpet.102.034140. View

Hu S, Franke R, Filipski K, Hu C, Orwick S, De Bruijn E . Interaction of imatinib with human organic ion carriers. Clin Cancer Res. 2008; 14(10):3141-8. DOI: 10.1158/1078-0432.CCR-07-4913. View

10.

Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker B . Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996; 56(1):100-4. View

11.

Lips K, Volk C, Schmitt B, Pfeil U, Arndt P, Miska D . Polyspecific cation transporters mediate luminal release of acetylcholine from bronchial epithelium. Am J Respir Cell Mol Biol. 2005; 33(1):79-88. DOI: 10.1165/rcmb.2004-0363OC. View

12.

Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark R . Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther. 2007; 83(2):258-64. DOI: 10.1038/sj.clpt.6100268. View

13.

OBrien S, Guilhot F, Larson R, Gathmann I, Baccarani M, Cervantes F . Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348(11):994-1004. DOI: 10.1056/NEJMoa022457. View

14.

McWeeney S, Pemberton L, Loriaux M, Vartanian K, Willis S, Yochum G . A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood. 2009; 115(2):315-25. PMC: 2808155. DOI: 10.1182/blood-2009-03-210732. View

15.

Manley P, Blasco F, Mestan J, Aichholz R . The kinetic deuterium isotope effect as applied to metabolic deactivation of imatinib to the des-methyl metabolite, CGP74588. Bioorg Med Chem. 2013; 21(11):3231-9. DOI: 10.1016/j.bmc.2013.03.038. View

16.

Burger H, Mathijssen R, Sparreboom A, Wiemer E . Can "specific" OCT1 inhibitors be used to determine OCT1 transporter activity toward imatinib?. Blood. 2013; 121(24):4965-6. DOI: 10.1182/blood-2013-03-493841. View

17.

Shu Y, Sheardown S, Brown C, Owen R, Zhang S, Castro R . Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007; 117(5):1422-31. PMC: 1857259. DOI: 10.1172/JCI30558. View

18.

Jonker J, Wagenaar E, Van Eijl S, Schinkel A . Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol Cell Biol. 2003; 23(21):7902-8. PMC: 207626. DOI: 10.1128/MCB.23.21.7902-7908.2003. View

19.

White D, Hughes T . Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib response. J Clin Oncol. 2012; 30(10):1144-5. DOI: 10.1200/JCO.2011.41.1090. View

20.

Ogura M, Morishima Y, Ohno R, Kato Y, Hirabayashi N, Nagura H . Establishment of a novel human megakaryoblastic leukemia cell line, MEG-01, with positive Philadelphia chromosome. Blood. 1985; 66(6):1384-92. View